> top > projects > spacy-test > docs > PubMed:3927361 > annotations
spacy-test Home  

PubMed:3927361 JSONTXT 2 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
spaCy_T0 0-7 NNPS denotes Effects
spaCy_T1 8-10 IN denotes of
spaCy_T2 11-24 JJ denotes discontinuous
spaCy_T3 25-29 NN denotes drug
spaCy_T4 30-44 NN denotes administration
spaCy_T5 45-47 IN denotes on
spaCy_T6 48-51 DT denotes the
spaCy_T7 52-63 NN denotes development
spaCy_T8 64-66 IN denotes of
spaCy_T9 67-75 NN denotes dopamine
spaCy_T10 76-84 NN denotes receptor
spaCy_T11 85-101 NN denotes supersensitivity
spaCy_T12 102-108 IN denotes during
spaCy_T13 109-116 JJ denotes chronic
spaCy_T14 117-132 NN denotes trifluoperazine
spaCy_T15 133-135 CC denotes or
spaCy_T16 136-152 JJ denotes cis-flupenthixol
spaCy_T17 153-167 NN denotes administration
spaCy_T18 168-170 TO denotes to
spaCy_T19 171-175 NNS denotes rats
spaCy_T20 175-176 . denotes .
spaCy_T21 177-181 NNS denotes Rats
spaCy_T22 182-190 VBD denotes received
spaCy_T23 191-201 JJ denotes continuous
spaCy_T24 202-204 CC denotes or
spaCy_T25 205-218 JJ denotes discontinuous
spaCy_T26 219-233 NN denotes administration
spaCy_T27 234-236 IN denotes of
spaCy_T28 237-252 NN denotes trifluoperazine
spaCy_T29 253-255 CC denotes or
spaCy_T30 256-272 NN denotes cis-flupenthixol
spaCy_T31 273-275 IN denotes in
spaCy_T32 276-284 NN denotes drinking
spaCy_T33 285-290 NN denotes water
spaCy_T34 291-294 IN denotes for
spaCy_T35 295-297 RB denotes up
spaCy_T36 298-300 TO denotes to
spaCy_T37 301-303 CD denotes 12
spaCy_T38 304-310 NNS denotes months
spaCy_T39 310-311 . denotes .
spaCy_T40 312-322 JJ denotes Continuous
spaCy_T41 323-326 CC denotes and
spaCy_T42 327-340 JJ denotes discontinuous
spaCy_T43 341-356 NN denotes trifluoperazine
spaCy_T44 357-371 NN denotes administration
spaCy_T45 372-375 VBD denotes had
spaCy_T46 376-378 DT denotes no
spaCy_T47 379-389 JJ denotes consistent
spaCy_T48 390-396 NN denotes effect
spaCy_T49 397-399 IN denotes on
spaCy_T50 400-419 JJ denotes apomorphine-induced
spaCy_T51 420-431 JJ denotes stereotyped
spaCy_T52 432-441 NN denotes behaviour
spaCy_T53 442-445 CC denotes and
spaCy_T54 446-451 EX denotes there
spaCy_T55 452-455 VBD denotes was
spaCy_T56 456-458 DT denotes no
spaCy_T57 459-469 NN denotes difference
spaCy_T58 470-477 IN denotes between
spaCy_T59 478-482 NN denotes drug
spaCy_T60 483-493 NNS denotes treatments
spaCy_T61 493-494 . denotes .
spaCy_T62 495-505 JJ denotes Continuous
spaCy_T63 506-509 CC denotes and
spaCy_T64 510-523 JJ denotes discontinuous
spaCy_T65 524-540 JJ denotes cis-flupenthixol
spaCy_T66 541-555 NN denotes administration
spaCy_T67 556-564 VBN denotes enhanced
spaCy_T68 565-584 JJ denotes apomorphine-induced
spaCy_T69 585-595 JJ denotes stereotypy
spaCy_T70 595-596 , denotes ,
spaCy_T71 597-600 CC denotes but
spaCy_T72 601-606 EX denotes there
spaCy_T73 607-610 VBD denotes was
spaCy_T74 611-613 DT denotes no
spaCy_T75 614-624 NN denotes difference
spaCy_T76 625-627 IN denotes in
spaCy_T77 628-631 DT denotes the
spaCy_T78 632-638 NN denotes effect
spaCy_T79 639-641 IN denotes of
spaCy_T80 642-645 DT denotes the
spaCy_T81 646-649 CD denotes two
spaCy_T82 650-654 NN denotes drug
spaCy_T83 655-665 NNS denotes treatments
spaCy_T84 665-666 . denotes .
spaCy_T85 667-671 DT denotes Both
spaCy_T86 672-682 JJ denotes continuous
spaCy_T87 683-686 CC denotes and
spaCy_T88 687-700 JJ denotes discontinuous
spaCy_T89 701-715 NN denotes administration
spaCy_T90 716-718 IN denotes of
spaCy_T91 719-734 NN denotes trifluoperazine
spaCy_T92 735-744 VBD denotes increased
spaCy_T93 745-748 DT denotes the
spaCy_T94 749-755 NN denotes number
spaCy_T95 756-758 IN denotes of
spaCy_T96 759-767 JJ denotes specific
spaCy_T97 768-776 JJ denotes striatal
spaCy_T98 777-789 NN denotes 3H-spiperone
spaCy_T99 790-797 JJ denotes binding
spaCy_T100 798-803 NNS denotes sites
spaCy_T101 804-805 -LRB- denotes (
spaCy_T102 805-809 NNP denotes Bmax
spaCy_T103 809-810 -RRB- denotes )
spaCy_T104 810-811 . denotes .
spaCy_T105 812-816 IN denotes Over
spaCy_T106 817-820 DT denotes the
spaCy_T107 821-827 NN denotes period
spaCy_T108 828-830 IN denotes of
spaCy_T109 831-840 NN denotes treatment
spaCy_T110 841-846 EX denotes there
spaCy_T111 847-850 VBD denotes was
spaCy_T112 851-853 DT denotes no
spaCy_T113 854-864 NN denotes difference
spaCy_T114 865-867 IN denotes in
spaCy_T115 868-871 DT denotes the
spaCy_T116 872-879 NNS denotes effects
spaCy_T117 880-882 IN denotes of
spaCy_T118 883-886 DT denotes the
spaCy_T119 887-896 JJ denotes different
spaCy_T120 897-907 NNS denotes treatments
spaCy_T121 907-908 . denotes .
spaCy_T122 909-919 JJ denotes Continuous
spaCy_T123 920-922 CC denotes or
spaCy_T124 923-936 JJ denotes discontinuous
spaCy_T125 937-953 JJ denotes cis-flupenthixol
spaCy_T126 954-960 NN denotes intake
spaCy_T127 961-964 VBD denotes did
spaCy_T128 965-968 RB denotes not
spaCy_T129 969-977 VB denotes increase
spaCy_T130 978-982 NNP denotes Bmax
spaCy_T131 983-988 IN denotes after
spaCy_T132 989-990 CD denotes 6
spaCy_T133 991-993 CC denotes or
spaCy_T134 994-996 CD denotes 12
spaCy_T135 997-1003 NNS denotes months
spaCy_T136 1004-1010 NN denotes intake
spaCy_T137 1010-1011 . denotes .
spaCy_T138 1012-1022 JJ denotes Continuous
spaCy_T139 1023-1025 CC denotes or
spaCy_T140 1026-1039 JJ denotes discontinuous
spaCy_T141 1040-1051 JJ denotes neuroleptic
spaCy_T142 1052-1061 NN denotes treatment
spaCy_T143 1062-1070 VBD denotes produced
spaCy_T144 1071-1073 DT denotes no
spaCy_T145 1074-1084 NN denotes difference
spaCy_T146 1085-1087 IN denotes in
spaCy_T147 1088-1098 JJ denotes functional
spaCy_T148 1099-1107 JJ denotes striatal
spaCy_T149 1108-1116 NN denotes dopamine
spaCy_T150 1117-1125 NN denotes receptor
spaCy_T151 1126-1134 NN denotes activity
spaCy_T152 1135-1137 IN denotes as
spaCy_T153 1138-1144 VBN denotes judged
spaCy_T154 1145-1147 IN denotes by
spaCy_T155 1148-1167 JJ denotes apomorphine-induced
spaCy_T156 1168-1179 JJ denotes stereotyped
spaCy_T157 1180-1189 NN denotes behaviour
spaCy_T158 1189-1190 . denotes .
spaCy_T159 1191-1197 NNP denotes Ligand
spaCy_T160 1198-1205 JJ denotes binding
spaCy_T161 1206-1213 NNS denotes studies
spaCy_T162 1214-1218 RB denotes also
spaCy_T163 1219-1226 VBP denotes suggest
spaCy_T164 1227-1231 IN denotes that
spaCy_T165 1232-1235 DT denotes the
spaCy_T166 1236-1243 JJ denotes overall
spaCy_T167 1244-1250 NN denotes change
spaCy_T168 1251-1253 IN denotes in
spaCy_T169 1254-1262 JJ denotes striatal
spaCy_T170 1263-1271 NN denotes receptor
spaCy_T171 1272-1280 NN denotes function
spaCy_T172 1281-1283 VBZ denotes is
spaCy_T173 1284-1287 RB denotes not
spaCy_T174 1288-1296 VBN denotes affected
spaCy_T175 1297-1299 IN denotes by
spaCy_T176 1300-1303 DT denotes the
spaCy_T177 1304-1307 NN denotes use
spaCy_T178 1308-1310 IN denotes of
spaCy_T179 1311-1312 DT denotes a
spaCy_T180 1313-1326 JJ denotes discontinuous
spaCy_T181 1327-1331 NN denotes drug
spaCy_T182 1332-1338 NN denotes regime
spaCy_T183 1338-1339 . denotes .
spaCy_R0 spaCy_T0 spaCy_T0 ROOT Effects,Effects
spaCy_R1 spaCy_T1 spaCy_T0 prep of,Effects
spaCy_R10 spaCy_T10 spaCy_T11 compound receptor,supersensitivity
spaCy_R100 spaCy_T100 spaCy_T95 pobj sites,of
spaCy_R101 spaCy_T101 spaCy_T100 punct (,sites
spaCy_R102 spaCy_T102 spaCy_T100 appos Bmax,sites
spaCy_R103 spaCy_T103 spaCy_T100 punct ),sites
spaCy_R104 spaCy_T104 spaCy_T92 punct .,increased
spaCy_R105 spaCy_T105 spaCy_T111 prep Over,was
spaCy_R106 spaCy_T106 spaCy_T107 det the,period
spaCy_R107 spaCy_T107 spaCy_T105 pobj period,Over
spaCy_R108 spaCy_T108 spaCy_T107 prep of,period
spaCy_R109 spaCy_T109 spaCy_T108 pobj treatment,of
spaCy_R11 spaCy_T11 spaCy_T8 pobj supersensitivity,of
spaCy_R110 spaCy_T110 spaCy_T111 expl there,was
spaCy_R111 spaCy_T111 spaCy_T111 ROOT was,was
spaCy_R112 spaCy_T112 spaCy_T113 det no,difference
spaCy_R113 spaCy_T113 spaCy_T111 attr difference,was
spaCy_R114 spaCy_T114 spaCy_T113 prep in,difference
spaCy_R115 spaCy_T115 spaCy_T116 det the,effects
spaCy_R116 spaCy_T116 spaCy_T114 pobj effects,in
spaCy_R117 spaCy_T117 spaCy_T116 prep of,effects
spaCy_R118 spaCy_T118 spaCy_T120 det the,treatments
spaCy_R119 spaCy_T119 spaCy_T120 amod different,treatments
spaCy_R12 spaCy_T12 spaCy_T0 prep during,Effects
spaCy_R120 spaCy_T120 spaCy_T117 pobj treatments,of
spaCy_R121 spaCy_T121 spaCy_T111 punct .,was
spaCy_R122 spaCy_T122 spaCy_T126 amod Continuous,intake
spaCy_R123 spaCy_T123 spaCy_T122 cc or,Continuous
spaCy_R124 spaCy_T124 spaCy_T122 conj discontinuous,Continuous
spaCy_R125 spaCy_T125 spaCy_T126 compound cis-flupenthixol,intake
spaCy_R126 spaCy_T126 spaCy_T129 nsubj intake,increase
spaCy_R127 spaCy_T127 spaCy_T129 aux did,increase
spaCy_R128 spaCy_T128 spaCy_T129 neg not,increase
spaCy_R129 spaCy_T129 spaCy_T129 ROOT increase,increase
spaCy_R13 spaCy_T13 spaCy_T14 amod chronic,trifluoperazine
spaCy_R130 spaCy_T130 spaCy_T129 dobj Bmax,increase
spaCy_R131 spaCy_T131 spaCy_T129 prep after,increase
spaCy_R132 spaCy_T132 spaCy_T135 nummod 6,months
spaCy_R133 spaCy_T133 spaCy_T132 cc or,6
spaCy_R134 spaCy_T134 spaCy_T132 conj 12,6
spaCy_R135 spaCy_T135 spaCy_T136 nsubj months,intake
spaCy_R136 spaCy_T136 spaCy_T131 pcomp intake,after
spaCy_R137 spaCy_T137 spaCy_T129 punct .,increase
spaCy_R138 spaCy_T138 spaCy_T142 amod Continuous,treatment
spaCy_R139 spaCy_T139 spaCy_T138 cc or,Continuous
spaCy_R14 spaCy_T14 spaCy_T12 pobj trifluoperazine,during
spaCy_R140 spaCy_T140 spaCy_T138 conj discontinuous,Continuous
spaCy_R141 spaCy_T141 spaCy_T142 amod neuroleptic,treatment
spaCy_R142 spaCy_T142 spaCy_T143 nsubj treatment,produced
spaCy_R143 spaCy_T143 spaCy_T143 ROOT produced,produced
spaCy_R144 spaCy_T144 spaCy_T145 det no,difference
spaCy_R145 spaCy_T145 spaCy_T143 dobj difference,produced
spaCy_R146 spaCy_T146 spaCy_T145 prep in,difference
spaCy_R147 spaCy_T147 spaCy_T151 amod functional,activity
spaCy_R148 spaCy_T148 spaCy_T151 amod striatal,activity
spaCy_R149 spaCy_T149 spaCy_T151 compound dopamine,activity
spaCy_R15 spaCy_T15 spaCy_T14 cc or,trifluoperazine
spaCy_R150 spaCy_T150 spaCy_T151 compound receptor,activity
spaCy_R151 spaCy_T151 spaCy_T146 pobj activity,in
spaCy_R152 spaCy_T152 spaCy_T153 mark as,judged
spaCy_R153 spaCy_T153 spaCy_T143 advcl judged,produced
spaCy_R154 spaCy_T154 spaCy_T153 agent by,judged
spaCy_R155 spaCy_T155 spaCy_T157 amod apomorphine-induced,behaviour
spaCy_R156 spaCy_T156 spaCy_T157 amod stereotyped,behaviour
spaCy_R157 spaCy_T157 spaCy_T154 pobj behaviour,by
spaCy_R158 spaCy_T158 spaCy_T143 punct .,produced
spaCy_R159 spaCy_T159 spaCy_T161 amod Ligand,studies
spaCy_R16 spaCy_T16 spaCy_T17 amod cis-flupenthixol,administration
spaCy_R160 spaCy_T160 spaCy_T161 amod binding,studies
spaCy_R161 spaCy_T161 spaCy_T163 nsubj studies,suggest
spaCy_R162 spaCy_T162 spaCy_T163 advmod also,suggest
spaCy_R163 spaCy_T163 spaCy_T163 ROOT suggest,suggest
spaCy_R164 spaCy_T164 spaCy_T174 mark that,affected
spaCy_R165 spaCy_T165 spaCy_T167 det the,change
spaCy_R166 spaCy_T166 spaCy_T167 amod overall,change
spaCy_R167 spaCy_T167 spaCy_T174 nsubjpass change,affected
spaCy_R168 spaCy_T168 spaCy_T167 prep in,change
spaCy_R169 spaCy_T169 spaCy_T171 amod striatal,function
spaCy_R17 spaCy_T17 spaCy_T14 conj administration,trifluoperazine
spaCy_R170 spaCy_T170 spaCy_T171 compound receptor,function
spaCy_R171 spaCy_T171 spaCy_T168 pobj function,in
spaCy_R172 spaCy_T172 spaCy_T174 auxpass is,affected
spaCy_R173 spaCy_T173 spaCy_T174 neg not,affected
spaCy_R174 spaCy_T174 spaCy_T163 ccomp affected,suggest
spaCy_R175 spaCy_T175 spaCy_T174 agent by,affected
spaCy_R176 spaCy_T176 spaCy_T177 det the,use
spaCy_R177 spaCy_T177 spaCy_T175 pobj use,by
spaCy_R178 spaCy_T178 spaCy_T177 prep of,use
spaCy_R179 spaCy_T179 spaCy_T182 det a,regime
spaCy_R18 spaCy_T18 spaCy_T14 prep to,trifluoperazine
spaCy_R180 spaCy_T180 spaCy_T182 amod discontinuous,regime
spaCy_R181 spaCy_T181 spaCy_T182 compound drug,regime
spaCy_R182 spaCy_T182 spaCy_T178 pobj regime,of
spaCy_R183 spaCy_T183 spaCy_T163 punct .,suggest
spaCy_R19 spaCy_T19 spaCy_T18 pobj rats,to
spaCy_R2 spaCy_T2 spaCy_T4 amod discontinuous,administration
spaCy_R20 spaCy_T20 spaCy_T0 punct .,Effects
spaCy_R21 spaCy_T21 spaCy_T22 nsubj Rats,received
spaCy_R22 spaCy_T22 spaCy_T22 ROOT received,received
spaCy_R23 spaCy_T23 spaCy_T26 amod continuous,administration
spaCy_R24 spaCy_T24 spaCy_T23 cc or,continuous
spaCy_R25 spaCy_T25 spaCy_T23 conj discontinuous,continuous
spaCy_R26 spaCy_T26 spaCy_T22 dobj administration,received
spaCy_R27 spaCy_T27 spaCy_T26 prep of,administration
spaCy_R28 spaCy_T28 spaCy_T27 pobj trifluoperazine,of
spaCy_R29 spaCy_T29 spaCy_T28 cc or,trifluoperazine
spaCy_R3 spaCy_T3 spaCy_T4 compound drug,administration
spaCy_R30 spaCy_T30 spaCy_T28 conj cis-flupenthixol,trifluoperazine
spaCy_R31 spaCy_T31 spaCy_T22 prep in,received
spaCy_R32 spaCy_T32 spaCy_T33 compound drinking,water
spaCy_R33 spaCy_T33 spaCy_T31 pobj water,in
spaCy_R34 spaCy_T34 spaCy_T22 prep for,received
spaCy_R35 spaCy_T35 spaCy_T37 quantmod up,12
spaCy_R36 spaCy_T36 spaCy_T37 quantmod to,12
spaCy_R37 spaCy_T37 spaCy_T38 nummod 12,months
spaCy_R38 spaCy_T38 spaCy_T34 pobj months,for
spaCy_R39 spaCy_T39 spaCy_T22 punct .,received
spaCy_R4 spaCy_T4 spaCy_T1 pobj administration,of
spaCy_R40 spaCy_T40 spaCy_T44 amod Continuous,administration
spaCy_R41 spaCy_T41 spaCy_T40 cc and,Continuous
spaCy_R42 spaCy_T42 spaCy_T40 conj discontinuous,Continuous
spaCy_R43 spaCy_T43 spaCy_T44 compound trifluoperazine,administration
spaCy_R44 spaCy_T44 spaCy_T45 nsubj administration,had
spaCy_R45 spaCy_T45 spaCy_T45 ROOT had,had
spaCy_R46 spaCy_T46 spaCy_T48 det no,effect
spaCy_R47 spaCy_T47 spaCy_T48 amod consistent,effect
spaCy_R48 spaCy_T48 spaCy_T45 dobj effect,had
spaCy_R49 spaCy_T49 spaCy_T48 prep on,effect
spaCy_R5 spaCy_T5 spaCy_T0 prep on,Effects
spaCy_R50 spaCy_T50 spaCy_T52 amod apomorphine-induced,behaviour
spaCy_R51 spaCy_T51 spaCy_T52 amod stereotyped,behaviour
spaCy_R52 spaCy_T52 spaCy_T49 pobj behaviour,on
spaCy_R53 spaCy_T53 spaCy_T45 cc and,had
spaCy_R54 spaCy_T54 spaCy_T55 expl there,was
spaCy_R55 spaCy_T55 spaCy_T45 conj was,had
spaCy_R56 spaCy_T56 spaCy_T57 det no,difference
spaCy_R57 spaCy_T57 spaCy_T55 attr difference,was
spaCy_R58 spaCy_T58 spaCy_T57 prep between,difference
spaCy_R59 spaCy_T59 spaCy_T60 compound drug,treatments
spaCy_R6 spaCy_T6 spaCy_T7 det the,development
spaCy_R60 spaCy_T60 spaCy_T58 pobj treatments,between
spaCy_R61 spaCy_T61 spaCy_T55 punct .,was
spaCy_R62 spaCy_T62 spaCy_T62 ROOT Continuous,Continuous
spaCy_R63 spaCy_T63 spaCy_T62 cc and,Continuous
spaCy_R64 spaCy_T64 spaCy_T62 conj discontinuous,Continuous
spaCy_R65 spaCy_T65 spaCy_T66 amod cis-flupenthixol,administration
spaCy_R66 spaCy_T66 spaCy_T67 nsubj administration,enhanced
spaCy_R67 spaCy_T67 spaCy_T67 ROOT enhanced,enhanced
spaCy_R68 spaCy_T68 spaCy_T69 compound apomorphine-induced,stereotypy
spaCy_R69 spaCy_T69 spaCy_T67 dobj stereotypy,enhanced
spaCy_R7 spaCy_T7 spaCy_T5 pobj development,on
spaCy_R70 spaCy_T70 spaCy_T67 punct ",",enhanced
spaCy_R71 spaCy_T71 spaCy_T67 cc but,enhanced
spaCy_R72 spaCy_T72 spaCy_T73 expl there,was
spaCy_R73 spaCy_T73 spaCy_T67 conj was,enhanced
spaCy_R74 spaCy_T74 spaCy_T75 det no,difference
spaCy_R75 spaCy_T75 spaCy_T73 attr difference,was
spaCy_R76 spaCy_T76 spaCy_T75 prep in,difference
spaCy_R77 spaCy_T77 spaCy_T78 det the,effect
spaCy_R78 spaCy_T78 spaCy_T76 pobj effect,in
spaCy_R79 spaCy_T79 spaCy_T78 prep of,effect
spaCy_R8 spaCy_T8 spaCy_T7 prep of,development
spaCy_R80 spaCy_T80 spaCy_T83 det the,treatments
spaCy_R81 spaCy_T81 spaCy_T83 nummod two,treatments
spaCy_R82 spaCy_T82 spaCy_T83 compound drug,treatments
spaCy_R83 spaCy_T83 spaCy_T79 pobj treatments,of
spaCy_R84 spaCy_T84 spaCy_T73 punct .,was
spaCy_R85 spaCy_T85 spaCy_T86 advmod Both,continuous
spaCy_R86 spaCy_T86 spaCy_T89 amod continuous,administration
spaCy_R87 spaCy_T87 spaCy_T86 cc and,continuous
spaCy_R88 spaCy_T88 spaCy_T86 conj discontinuous,continuous
spaCy_R89 spaCy_T89 spaCy_T92 nsubj administration,increased
spaCy_R9 spaCy_T9 spaCy_T11 compound dopamine,supersensitivity
spaCy_R90 spaCy_T90 spaCy_T89 prep of,administration
spaCy_R91 spaCy_T91 spaCy_T90 pobj trifluoperazine,of
spaCy_R92 spaCy_T92 spaCy_T92 ROOT increased,increased
spaCy_R93 spaCy_T93 spaCy_T94 det the,number
spaCy_R94 spaCy_T94 spaCy_T92 dobj number,increased
spaCy_R95 spaCy_T95 spaCy_T94 prep of,number
spaCy_R96 spaCy_T96 spaCy_T100 amod specific,sites
spaCy_R97 spaCy_T97 spaCy_T100 amod striatal,sites
spaCy_R98 spaCy_T98 spaCy_T100 nmod 3H-spiperone,sites
spaCy_R99 spaCy_T99 spaCy_T100 amod binding,sites